GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Capex-to-Operating-Income

Hemostemix (TSXV:HEM) Capex-to-Operating-Income : 0.00 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hemostemix Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Hemostemix's Capital Expenditure for the three months ended in Sep. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was C$-0.96 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Hemostemix Capex-to-Operating-Income Historical Data

The historical data trend for Hemostemix's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Capex-to-Operating-Income Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hemostemix's Capex-to-Operating-Income

For the Biotechnology subindustry, Hemostemix's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Hemostemix's Capex-to-Operating-Income falls into.



Hemostemix Capex-to-Operating-Income Calculation

Hemostemix's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -2.157
=N/A

Hemostemix's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.964
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemostemix  (TSXV:HEM) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Hemostemix Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Hemostemix's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemostemix Business Description

Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Executives
Thomas Smeenk Director
Peter Alan Lacey Director
Loran Swanberg Director
Blake Wood 10% Security Holder
Ravi Jain Senior Officer

Hemostemix Headlines

No Headlines